Two people in their 60s who received the shot were diagnosed with Guillain-Barre syndrome, out of about 20,000 vaccine recipients who participated in Pfizer’s Phase 3 clinical trial, according ...

References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.

The Johnson & Johnson COVID-19 vaccine has been linked to Guillain Barré Syndrome in rare cases. Experts explain what to know about the condition.

Some people who got the Johnson & Johnson/Janssen COVID-19 vaccine (the one-dose vaccine) have developed a condition known as Guillain-Barré syndrome. It’s happened often enough that the FDA ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...

Two people in the Johnson & Johnson COVID-19 vaccine trial developed Guillain-Barré syndrome, but it's highly doubtful the vaccine is to blame, according to a just-published case study.

A haywire immune system, attacking healthy nerves, causes the disorder. U.S. health authorities added a warning to the label of J&J’s Covid-19 vaccine after finding 100 reports.

Guillain-Barre syndrome occurs when the body’s immune system mistakenly attacks some of its nerve cells, causing muscle weakness and sometimes paralysis that typically is temporary.

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy ...

References: US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy.